Prostate Cancer Canada's Rock the Road Raffle sells out for 5th consecutive year

Proceeds to fund research in Ontario

March 1, 2017 – TORONTO, ON – For the fifth year and counting, Prostate Cancer Canada’s (PCC) Rock the Road Raffle brought together Ontarians from all walks of life to both support an important cause and have a chance to win a one-of-a-kind dream car. 

Photo Credit: The Official Canadian International AutoShow

After months of tickets sales that raised over $400,000 for research in the province, Justin Belmur of North York was announced at the 2017 Canadian International AutoShow as the lucky new owner of a custom made Dodge Hellcat valued at more than $113,000. The big draw took place on Friday, February 24.

Also announced at the AutoShow that day were the winners of this year’s second and third Raffle prizes. Ron Crockett of Mississauga won a two-night stay on a luxury yacht including round-trip airfare for two in Economy Class to Miami valued at over $14,000, and Paul Nantais of Windsor won a Honda Indy Toronto VIP Race Package for four, including hotel, valued at $7,000.

“On behalf of the 1 in 7 Canadian men who will be diagnosed with prostate cancer in their lifetime, I would like to thank everyone who made this year’s Rock the Road Raffle another huge success for prostate cancer research,” said PCC’s President and CEO, Rocco Rossi. “This raffle has been and will continue to be a real driving force behind research that is bringing greater hope to Canadian families.”

The Rock the Road Raffle would not be possible without the support of sponsors that make it possible. In particular, the Trillium Automobile Dealers Association has demonstrated tremendous generosity and commitment to the cause by donating all 5 of the superb vehicles that have been raffled off to date. BG Signature donated the trip to Miami, and Honda Indy Toronto donated the VIP Race Package. The Canadian International AutoShow donated space at their event to showcase the car, sell the remaining tickets, and host the official draw.

“Thanks to organizational leadership and dedication of this magnitude, Prostate Cancer Canada has raised a total of over $1.3 million for prostate cancer research since the raffle’s first year, helping move us closer to the ultimate goal of leaving the most common male cancer in our dust – and making some automotive dreams come true in the process,” Rossi explained.
About Prostate Cancer Canada
Prostate Cancer Canada is the leading national foundation dedicated to the elimination of the most common cancer in men through research, advocacy, education, support and awareness. As one of the largest investors in prostate cancer research in Canada, Prostate Cancer Canada is committed to continuous discovery in the areas of prevention, diagnosis, treatment, and support.
For more information please contact:
Adam Miller
Manager, Communications
Prostate Cancer Canada
416 441 2131 ext. 235

Plaid for Dad

Subscribe to our free monthly e-newsletter!

* indicates required


PCC Spotlight
Honouring dad this Father’s Day the Canadian way: In plaid

TORONTO, ON – (May 8, 2018) – Plaid replaces business-casual on Friday, June 15 as hundreds of thousands of Canadians don the iconic Canadian attire all to honour dad and end prostate cancer.

The Finger – A tried and true method to save lives

TORONTO, CANADA (May 8, 2018) – Every day, more and more methods to detect prostate cancer are being explored, but the tried and true methods of a digital rectal examination (DRE) – where a healthcare professional inserts a gloved finger into the rectum to check for abnormalities, paired with a blood test known as the prostate-specific antigen (PSA) test – which you can get through your family doctor, are still the long-standing proven ways to save a life.

Landmark study links tumour evolution to prostate cancer severity

Toronto (April 19, 2018) – Findings from Canadian Prostate Cancer Genome Network (CPC-GENE) researchers and their collaborators, published today in Cell, show that the aggressiveness of an individual prostate cancer can be accurately assessed by looking at how that tumour has evolved.

Click here for news archive